Soleno Theraptcs Rg
SLNO
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
11/04/2025 - 02:00:00
Bid
11/04/2025 - 13:03:59
Bid
Volume 		Ask
11/04/2025 - 13:03:59
Ask
Volume
65.65
-1.51 ( -2.25% )
63.86
100
70.00
1,500
More information
Analysis by TheScreener
31.10.2025
Evaluation Slightly negative  
Interest Weak  
Sensibility High  
Analysis date: 31.10.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 31.10.2025.
Interest
  Weak
Two stars since 31.10.2025.
Earnings Rev Trend
  Negative
 
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 17.10.2025 at a price of 65.47.
Evaluation
  Undervalued
 
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 28.10.2025.
4wk Rel Perf
  -2.92%
 
The four-week dividend-adjusted underperformance versus SP500 is 2.92%.
Sensibility
  High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -0.78%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.79%.
Mkt Cap in $bn
  3.57
With a market capitalization between $2 & $8bn, SOLENO THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  17.23
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  6.79
The estimated PE is for the year 2028.
LT Growth
  117.05%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  79
For 1% of index variation, the stock varies on average by 0.79%.
Correlation
  0.22
Stock movements are strongly independent of index variations.
Value at Risk
  35.98
The value at risk is estimated at USD 35.98. The risk is therefore 53.57%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  15.07.2025